Trial success for Allergan’s anti-CGRP migraine drug
The first of two pivotal Phase III clinical trials evaluating Allergan’s experimental anti-CGRP migraine drug ubrogepant has met its key goal.
Read More
Tag: ACHIEVE I
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
